Exhibit 99.1 | | Q3 2025 | | Q3 2024 | | | --- | --- | --- | --- | --- | | GAAP EPS from continuing operations (GAAP EPS) | $| 1.55 |$ | 2.48 | | Special items: | | | | | | Net costs for significant litigation | | 0.19 | | 0.51 | | (Increase) decrease in value of Solventum ownership | | 0.13 | | (1.05) | | Manufactured PFAS products | | — | | 0.04 | | Loss on business divestitures | | 0.30 | | — | | Transformation costs | | 0.02 | | — | | Adjusted EPS from continuing operations (adjusted EPS) | $ | 2.19 | ...